Modeling Sarcoglycanopathy in Danio rerio
Authors:
- Francesco Dalla BarbaFBFrancesco Dalla Barba
- Michela SoardiMSMichela Soardi
- Leila MouhibLMLeila Mouhib
- Giovanni RisatoGRGiovanni Risato
- Eylem Emek AkyürekEAEylem Emek Akyürek
- Tyrone Lucon-XiccatoTyrone Lucon-Xiccato
- Martina ScanoMSMartina Scano
- Alberto BenetolloABAlberto Benetollo
- Roberta SacchettoRSRoberta Sacchetto
- Isabelle RichardIRIsabelle Richard
- Francesco ArgentonFrancesco Argenton
- Cristiano BertolucciCristiano Bertolucci
Open Access
- 11 August 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (16) , 12707
Abstract
Sarcoglycanopathies, also known as limb girdle muscular dystrophy 3-6, are rare muscular dystrophies characterized, although heterogeneous, by high disability, with patients often wheelchair-bound by late adolescence and frequently developing respiratory and cardiac problems. These diseases are currently incurable, emphasizing the importance of effective treatment strategies and the necessity of animal models for drug screening and therapeutic verification. Using the CRISPR/Cas9 genome editing technique, we generated and characterized δ-sarcoglycan and β-sarcoglycan knockout zebrafish lines, which presented a progressive disease phenotype that worsened from a mild larval stage to distinct myopathic features in adulthood. By subjecting the knockout larvae to a viscous swimming medium, we were able to anticipate disease onset. The δ-SG knockout line was further exploited to demonstrate that a δ-SG missense mutant is a substrate for endoplasmic reticulum-associated degradation (ERAD), indicating premature degradation due to protein folding defects. In conclusion, our study underscores the utility of zebrafish in modeling sarcoglycanopathies through either gene knockout or future knock-in techniques. These novel zebrafish lines will not only enhance our understanding of the disease’s pathogenic mechanisms, but will also serve as powerful tools for phenotype-based drug screening, ultimately contributing to the development of a cure for sarcoglycanopathies.Keywords
Funding Information
- Association Françoise contre les Myopathies (18620, 23765, MDA 577888, FAR2022)
- Muscular Dystrophy Association (18620, 23765, MDA 577888, FAR2022)
- University of Ferrara research (18620, 23765, MDA 577888, FAR2022)
This publication has 87 references indexed in Scilit:
- The proteasomal inhibitor MG132 prevents muscular dystrophy in zebrafishPLoS Currents, 2011
- Drug screening in a zebrafish model of Duchenne muscular dystrophyProceedings of the National Academy of Sciences, 2011
- T-tubule biogenesis and triad formation in skeletal muscle and implication in human diseasesSkeletal Muscle, 2011
- δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approachesSkeletal Muscle, 2011
- Intraperitoneal Injection into Adult ZebrafishJournal of Visualized Experiments, 2010
- Retro-orbital Injection in Adult ZebrafishJournal of Visualized Experiments, 2009
- Inhibition of Proteasome Activity Promotes the Correct Localization of Disease-Causing α-Sarcoglycan Mutants in HEK-293 Cells Constitutively Expressing β-, γ-, and δ-SarcoglycanThe American Journal of Pathology, 2008
- A common disease-associated missense mutation in alpha-sarcoglycan fails to cause muscular dystrophy in miceHuman Molecular Genetics, 2008
- Zebrafish orthologs of human muscular dystrophy genesBMC Genomics, 2007
- Stages of embryonic development of the zebrafishDevelopmental Dynamics, 1995